M
Michael M. Lieber
Researcher at Mayo Clinic
Publications - 285
Citations - 29022
Michael M. Lieber is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 75, co-authored 285 publications receiving 28059 citations. Previous affiliations of Michael M. Lieber include University of Rochester & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Scott M. Lippman,Eric A. Klein,Eric A. Klein,Phyllis J. Goodman,M. Scott Lucia,Ian M. Thompson,Leslie G. Ford,Howard L. Parnes,Lori M. Minasian,J. Michael Gaziano,Jo Ann Hartline,J. Kellogg Parsons,James D. Bearden,E. David Crawford,Gary E. Goodman,Jaime Claudio,Eric Winquist,Elise D. Cook,Daniel D. Karp,Philip J. Walther,Michael M. Lieber,Alan R. Kristal,Amy K. Darke,Kathryn B. Arnold,Patricia A. Ganz,Regina M. Santella,Demetrius Albanes,Philip R. Taylor,Jeffrey L. Probstfield,T. J. Jagpal,John Crowley,Frank L. Meyskens,Laurence H. Baker,Charles A. Coltman +33 more
TL;DR: Selenium or vitamin E, alone or in combination at the doses and formulations used, did not prevent prostate cancer in this population of relatively healthy men.
Journal ArticleDOI
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
John D. McConnell,Claus G. Roehrborn,Oliver Bautista,Gerald L. Andriole,Christopher M. Dixon,John W. Kusek,Herbert Lepor,Kevin T. McVary,Leroy M. Nyberg,Harry Clarke,E. David Crawford,Ananias C. Diokno,John P. Foley,Harris E. Foster,Stephen C. Jacobs,Steven A. Kaplan,Karl J. Kreder,Michael M. Lieber,M. Scott Lucia,Gary J. Miller,Mani Menon,Douglas F. Milam,Joe W. Ramsdell,Noah S. Schenkman,Kevin M. Slawin,Joseph A. Smith +25 more
TL;DR: Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
Journal ArticleDOI
Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein,Ian M. Thompson,Catherine M. Tangen,John Crowley,M. Scott Lucia,Phyllis J. Goodman,Lori M. Minasian,Leslie G. Ford,Howard L. Parnes,J. Michael Gaziano,Daniel D. Karp,Michael M. Lieber,Philip J. Walther,Laurence Klotz,J. Kellogg Parsons,Joseph L. Chin,Amy K. Darke,Scott M. Lippman,Gary E. Goodman,Frank L. Meyskens,Laurence H. Baker +20 more
TL;DR: Dietary supplementation with vitamin E significantly increased the risk of prostate cancer among healthy men in relatively healthy men.
Journal ArticleDOI
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Joseph E. Oesterling,Steven J. Jacobsen,Christopher G. Chute,Harry A. Guess,Cynthia J. Girman,Laurei A. Panser,Michael M. Lieber +6 more
TL;DR: The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage.